BioCryst Pharmaceuticals
BCRX
286 hedge funds and large institutions have $1.48B invested in BioCryst Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 37 funds opening new positions, 94 increasing their positions, 107 reducing their positions, and 41 closing their positions.
38% more call options, than puts
Call options by funds: $6.78M | Put options by funds: $4.9M
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
10% less first-time investments, than exits
New positions opened: 37 | Existing positions closed: 41
1.74% less ownership
Funds ownership: 94.23% → 92.5% (-1.7%)
3% less funds holding
Funds holding: 294 → 286 (-8)
11% less capital inflows, than outflows
Capital inflows: $221M | Capital outflows: $249M
12% less repeat investments, than reductions
Existing positions increased: 94 | Existing positions reduced: 107
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deerfield Management
New York
|
+$62.3M |
| 2 |
Hood River Capital Management
Palm Beach Gardens,
Florida
|
+$19.8M |
| 3 |
Jane Street
New York
|
+$13.1M |
| 4 |
State Street
Boston,
Massachusetts
|
+$10.8M |
| 5 |
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$10.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Avoro Capital Advisors
New York
|
-$27.1M |
| 2 |
D.E. Shaw & Co
New York
|
-$22.3M |
| 3 |
Walleye Capital
New York
|
-$17.3M |
| 4 |
Voloridge Investment Management
Jupiter,
Florida
|
-$12.6M |
| 5 |
Millennium Management
New York
|
-$12M |
BCRX Hedge Fund Activity: Q3 2025 in Review
286 of the 7,653 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q3 2025, worth a combined $1.48B — down 17% from $1.77B a quarter earlier.
Sellers outnumbered buyers: 41 funds closed out of BCRX and 37 opened new positions — a net loss of 4 holders — while 107 trimmed existing stakes and 94 added.
The largest buyer was Deerfield Management, adding an estimated $62.3M. The largest seller was Avoro Capital Advisors, cutting an estimated $27.1M.
- 286 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q3 2025, down from 294 in Q2 2025.
- Funds reported $1.48B of BioCryst Pharmaceuticals stock for Q3 2025, down 17% quarter-over-quarter.
- 37 funds opened new BioCryst Pharmaceuticals positions in Q3 2025 and 41 closed out, a net change of -4 holders.
- The largest BioCryst Pharmaceuticals buyer in Q3 2025 was Deerfield Management, an estimated $62.3M added.
- The largest BioCryst Pharmaceuticals seller in Q3 2025 was Avoro Capital Advisors, an estimated $27.1M sold.
Based on aggregated 13F filings for Q3 2025.